NCT00378690View on ClinicalTrials.gov

A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD

PHASE3CompletedINTERVENTIONAL
Enrollment

706

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2011

Study Completion Date

December 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

leuprorelin acetate

LHRH antagonist

Trial Locations (71)

1070

Brussels

1106

Budapest

1200

Brussels

2800

Tatabánya

4000

Liège

4400

Nyíregyháza

5000

Szolnok

7400

Kaposvár

7521

Olomouc

8003

Barcelona

8035

Barcelona

8036

Barcelona

8200

Veszprém

13915

Marseille

14033

Caen

19230

Hagenow

20033

Desio

24128

Bergamo

28041

Madrid

28922

Alcorcón

29609

Brest

31054

Toulouse

33073

Bordeaux

38043

Grenoble

40113

Ústí nad Labem

40138

Bologna

43100

Parma

44093

Nantes

46009

Valencia

46660

Jablonec nad Nisou

53275

Ploemeur

53474

Bad Neuenaher

54290

Trier

65691

Bmo

69310

Pierre-Bénite

75007

Paris

75014

Paris

76031

Rouen

83000

Toulon

84000

Avignon

90982

Skalica

91101

Trenčín

92151

Suresnes

94275

Paris

95301

Cergy-Pontoise

115478

Moscow

125101

Moscow

125284

Moscow

198013

Saint Petersburg

198255

Saint Petersburg

Unknown

Brussels

Ancona

Bari

Chieti

Messina

Milan

A Coruña

Granada

Madrid

B-3000

Leuven

FIN-80210

Joensuu

FIN-33521

Tampere

02625

Bautzen

01307

Dresden

01324

Dresden

06132

Halle

06333

Hettstedt

04105

Leipzig

01844

Neustadt in Sachsen

00189

Roma

03659

Martin

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY